Back to top
more

Proteostasis Therapeutics, Inc. (PTI)

(Delayed Data from NSDQ)

$1.08 USD

1.08
913,756

+0.07 (6.93%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.07 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Proteostasis Therapeutics (PTI) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Proteostasis Therapeutics (PTI) has been struggling lately, but the selling pressure may be coming to an end soon.

Sanghamitra Saha headshot

Forget Bargain Hunting: Play 5 Stocks With Rising P/E

by Sanghamitra Saha

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Sanghamitra Saha headshot

Bet on Rising P/E With These 5 Top Stocks

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Proteostasis Therapeutics (PTI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Proteostasis (PTI) delivered earnings and revenue surprises of 19.05% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Bet on Rising Price-to-Earnings With 5 Top Stocks

by Sanghamitra Saha

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Vertex's Kalydeco Wins Approval in EU for CF in Children

by Zacks Equity Research

Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene.

Proteostasis Therapeutics (PTI) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Proteostasis (PTI) delivered earnings and revenue surprises of 17.39% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include: JAKKS, Avinger, Energous, FireEye and Proteostasis

by Zacks Equity Research

Zacks.com featured highlights include: JAKKS, Avinger, Energous, FireEye and Proteostasis

Sanghamitra Saha headshot

5 Top Stocks With Rising P/E to Bet On

by Sanghamitra Saha

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Will Proteostasis Therapeutics (PTI) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Proteostasis (PTI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.

The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis

Tirthankar Chakraborty headshot

US Dollar Flexes Muscles Against Other Currencies: 5 Winners

by Tirthankar Chakraborty

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics

Tirthankar Chakraborty headshot

Coronavirus to Hit Apple Sales: Invest in Domestic Producers

by Tirthankar Chakraborty

With the coronavirus threat increasing, it's quite evident that companies having significant exposure to China and the global economy are vulnerable. However, domestic producers of goods should remain unaffected.

Is Proteostasis Therapeutics (PTI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (PTI) Outperforming Other Medical Stocks This Year?

Will Proteostasis Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Proteostasis Therapeutics

Options Traders Expect Huge Moves in Proteostasis (PTI) Stock

by Zacks Equity Research

Investors need to pay close attention to Proteostasis (PTI) stock based on the movements in the options market lately.

Proteostasis Therapeutics (PTI) in Focus: Stock Moves 7.3% Higher

by Zacks Equity Research

Proteostasis Therapeutics (PTI) shares rose more than 7% in the last trading session, amid huge volumes.

Proteostasis Therapeutics, Inc. (PTI) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Proteostasis Therapeutics, Inc. (PTI).

Sweta Killa headshot

Biotech Tops in November: Best ETFs & Stocks

by Sweta Killa

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

Are Options Traders Betting on a Big Move in Proteostasis Therapeutics (PTI) Stock?

by Zacks Equity Research

Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.

Sanghamitra Saha headshot

Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

by Sanghamitra Saha

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Proteostasis Therapeutics (PTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Enters Into Collaboration With Privately-Held Ribometrix

by Zacks Equity Research

Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.